Type 2 Diabetes CRISPR Knockout Models for Drug Discovery

Type 2 Diabetes (T2D) is a chronic metabolic disorder affecting over 537 million adults worldwide as of 2021, according to the World Health Organization (WHO). The global prevalence is projected to rise to 643 million by 2030. T2D accounts for approximately 90% of all diabetes cases and is a leading cause of cardiovascular disease, kidney failure, blindness, and lower limb amputation. Key risk factors include obesity, physical inactivity, poor diet, and genetic predisposition. The economic burden is substantial, with global health expenditures exceeding $966 billion annually (WHO, 2021).

T2D is an ideal disease for mechanistic studies due to its complex interplay between insulin resistance and beta-cell dysfunction. The availability of large-scale public datasets, such as those from the UK Biobank and the Diabetes Genetics Initiative, provides rich genetic and phenotypic data. Open questions include the molecular mechanisms of beta-cell dedifferentiation, the role of epigenetic modifications, and the identification of novel therapeutic targets. Gene-edited cell models are essential tools for dissecting these pathways.

The pathogenesis of T2D involves several interconnected pathways:

1. Insulin Signaling Pathway: Insulin binds to the insulin receptor (INSR), activating IRS1/2, PI3K, and AKT, leading to glucose uptake via GLUT4 translocation. Defects in this pathway cause insulin resistance.

2. Beta-cell Dysfunction: Reduced insulin secretion due to impaired glucose sensing, mitochondrial dysfunction, and ER stress. Key transcription factors include PDX1, MAFA, and NEUROD1.

3. Incretin Pathway: GLP-1 and GIP hormones enhance insulin secretion. Dysregulation of GLP1R signaling contributes to impaired glucose homeostasis.

4. Adipokine Signaling: Adipose tissue releases adipokines (e.g., adiponectin, leptin, TNF-alpha) that modulate insulin sensitivity. Chronic inflammation promotes insulin resistance.

Data from ClinVar, NCBI Gene, and large-scale GWAS studies.

Key deregulated networks in T2D include:

• • Insulin/PI3K/AKT Pathway: Reduced AKT phosphorylation leads to impaired GLUT4 translocation.
• • Wnt/beta-catenin Pathway: TCF7L2 is a key transcription factor; variants affect beta-cell proliferation.
• • MAPK/ERK Pathway: Chronic hyperglycemia activates ERK, contributing to insulin resistance.
• • NF-kB Pathway: Pro-inflammatory cytokines (TNF-alpha, IL-6) activate NF-kB, promoting insulin resistance.
• • AMPK Pathway: Reduced AMPK activity impairs mitochondrial function and glucose uptake.

Organoids derived from human pluripotent stem cells (hPSCs) offer a more physiologically relevant model, allowing study of beta-cell development and function in a 3D context.

Common animal models for T2D research include:

• • High-Fat Diet (HFD) Induced: Mice fed a high-fat diet develop obesity and insulin resistance.
• • Genetic Models: db/db (leptin receptor deficient) and ob/ob (leptin deficient) mice.
• • Zucker Diabetic Fatty (ZDF) Rat: A model of obesity and insulin resistance.
• • Goto-Kakizaki (GK) Rat: A non-obese model of T2D with beta-cell dysfunction.
• • Humanized Mouse Models: Mice engrafted with human islets or expressing human genes (e.g., TCF7L2 variants).

CRISPR/Cas9 gene editing enables the creation of isogenic cell lines with precise genetic modifications, such as knockouts, knock-ins, and reporter lines. For T2D research, examples include:

• • TCF7L2 knockout in EndoC-betaH1 cells: To study the role of TCF7L2 in beta-cell function.
• • PPARG Pro12Ala knock-in in 3T3-L1 cells: To investigate the effect of this variant on adipogenesis.
• • KCNJ11 E23K knock-in in INS-1 cells: To model impaired insulin secretion.
• • GLP1R knockout in MIN6 cells: To study incretin signaling.

Commercially available, sequence-verified gene-edited cell lines accelerate research by providing reproducible models for functional studies and drug screening.

Gene-edited cell lines are used to validate the function of genes identified in GWAS studies. For example, TCF7L2 knockout in beta-cell lines leads to reduced insulin secretion and impaired glucose-stimulated insulin release, confirming its role in T2D. Similarly, PPARG knockout in adipocytes impairs adipogenesis and insulin sensitivity.

Isogenic pairs (wild-type vs. mutant) enable high-throughput screening for compounds that selectively target mutant cells. For example, KCNJ11 E23K knock-in cells can be used to screen for drugs that enhance insulin secretion. Resistance to GLP-1 receptor agonists can be modeled using GLP1R knockout lines.

CRISPR-based synthetic lethality screens identify genes that are essential only in the context of specific mutations. For T2D, screens in TCF7L2 knockout cells may reveal novel drug targets. Additionally, reporter lines (e.g., insulin-GFP) allow real-time monitoring of beta-cell function and can be used to identify biomarkers of beta-cell stress.